Wall Street analysts expect Editas Medicine Inc (NASDAQ:EDIT) to announce $2.55 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Editas Medicine’s earnings. The lowest sales estimate is $2.00 million and the highest is $3.10 million. Editas Medicine posted sales of $960,000.00 in the same quarter last year, which would indicate a positive year over year growth rate of 165.6%. The business is expected to report its next earnings report on Monday, November 6th.

According to Zacks, analysts expect that Editas Medicine will report full year sales of $2.55 million for the current financial year, with estimates ranging from $9.80 million to $29.93 million. For the next financial year, analysts forecast that the firm will report sales of $23.31 million per share, with estimates ranging from $15.00 million to $39.03 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Editas Medicine.

Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings data on Wednesday, August 9th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.01. The company had revenue of $3.10 million for the quarter, compared to the consensus estimate of $2.20 million. Editas Medicine had a negative return on equity of 54.18% and a negative net margin of 853.70%. The business’s revenue was down 8.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.54) earnings per share.

Several analysts have commented on the stock. Cann reiterated a “hold” rating on shares of Editas Medicine in a research report on Thursday, August 10th. J P Morgan Chase & Co set a $27.00 price objective on shares of Editas Medicine and gave the company a “hold” rating in a research report on Wednesday, August 9th. SunTrust Banks, Inc. began coverage on shares of Editas Medicine in a research report on Thursday, July 13th. They issued a “hold” rating and a $17.00 price objective for the company. Zacks Investment Research cut shares of Editas Medicine from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Editas Medicine in a research report on Tuesday, July 18th. Five investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $25.03.

In related news, insider Katrine Bosley sold 16,666 shares of the company’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $20.02, for a total value of $333,653.32. Following the completion of the sale, the insider now owns 1,431,095 shares in the company, valued at approximately $28,650,521.90. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Kevin Bitterman sold 1,000,000 shares of the company’s stock in a transaction on Monday, May 22nd. The shares were sold at an average price of $17.00, for a total transaction of $17,000,000.00. The disclosure for this sale can be found here.

Several hedge funds have recently added to or reduced their stakes in EDIT. IHT Wealth Management LLC purchased a new stake in Editas Medicine during the second quarter worth approximately $107,000. DekaBank Deutsche Girozentrale purchased a new stake in Editas Medicine during the second quarter worth approximately $127,000. Bank of America Corp DE boosted its stake in Editas Medicine by 72.2% in the first quarter. Bank of America Corp DE now owns 5,936 shares of the company’s stock worth $133,000 after buying an additional 2,489 shares in the last quarter. Legal & General Group Plc boosted its stake in Editas Medicine by 308.4% in the second quarter. Legal & General Group Plc now owns 8,654 shares of the company’s stock worth $145,000 after buying an additional 6,535 shares in the last quarter. Finally, Creative Planning boosted its stake in Editas Medicine by 8,910.9% in the second quarter. Creative Planning now owns 9,101 shares of the company’s stock worth $153,000 after buying an additional 9,000 shares in the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Shares of Editas Medicine (NASDAQ EDIT) opened at 20.65 on Wednesday. Editas Medicine has a 1-year low of $12.43 and a 1-year high of $29.20. The company’s market capitalization is $845.12 million. The stock’s 50 day moving average price is $17.42 and its 200 day moving average price is $19.08.

TRADEMARK VIOLATION NOTICE: “$2.55 Million in Sales Expected for Editas Medicine Inc (EDIT) This Quarter” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/08/16/2-55-million-in-sales-expected-for-editas-medicine-inc-edit-this-quarter.html.

Editas Medicine Company Profile

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Get a free copy of the Zacks research report on Editas Medicine (EDIT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc and related companies with MarketBeat.com's FREE daily email newsletter.